OncoMatch/Clinical Trials/NCT06695026
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Is NCT06695026 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including RZ-001 Dose 1 and RZ-001 Dose 2 for hepatocellular carcinoma (hcc).
Treatment: RZ-001 Dose 1 · RZ-001 Dose 2 · RZ-001 Dose 3 — This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: TERT positive expression
hTERT positive expression confirmed during the screening period
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Liver function
child-pugh score of a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify